Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Edesa Biotech, Inc.

Market Cap 50.2M 43.36M 39.96M 37.4M 70.09M 4.77B 71.18M 472M 184M 2.32B 188M 184M 8.04B P/E Ratio 2026 *
-3.6x
P/E Ratio 2027 * -2.88x
Enterprise Value 50.2M 43.36M 39.96M 37.4M 70.09M 4.77B 71.18M 472M 184M 2.32B 188M 184M 8.04B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
81.13%
Yield 2026 *
-
Yield 2027 * -
1 day+5.58%
1 week+6.23%
Current month-19.67%
1 month-56.29%
3 months-9.09%
6 months+233.33%
Current year+308.45%
1 week 4.56
Extreme 4.56
6.27
1 month 4.56
Extreme 4.56
15.45
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 2015-07-31
Director of Finance/CFO 57 2025-04-30
President 48 2019-06-06
Director TitleAgeSince
Chairman 50 2019-06-06
Director/Board Member 55 2019-06-06
Chairman 70 -
Date Insider Type Main position Quantity % Market Cap.
05-31Free

Founder

1,671 0.0188%
05-26Free

Chief Financial Officer

64,609 0.7271%
05-26Free

Chairperson

64,609 0.7271%
Change 5-day change 1-year change 3-year change Capi.($)
+2.65%+6.23%+196.68%-1.59% 50.2M
+1.03%+7.52%+54.74%+114.98% 55.58B
+2.72%+3.06%+53.28%+47.85% 43.47B
+1.12%+2.79%-13.71%-17.53% 22.64B
+1.17%+3.85%+1.00%+401.79% 20.96B
+3.81%-4.13%+16.62%-30.70% 15.79B
+0.15%+2.24%+9.06%-39.50% 15.3B
-0.69%+0.82%+27.17%+178.31% 13.45B
+5.27%+6.41%+21.05% - 11.74B
+1.61%+1.17%+90.79%+212.97% 10.96B
Average +2.18%-1.80%+45.67%+96.29% 20.99B
Weighted average by Cap. +1.71%+1.60%+33.76%+101.61%

Financials

2026 *2027 *
Net sales - -
Net income -13.5M -11.66M -10.74M -10.06M -18.85M -1.28B -19.14M -127M -49.47M -625M -50.67M -49.59M -2.16B -26.75M -23.1M -21.29M -19.93M -37.35M -2.54B -37.93M -251M -98.01M -1.24B -100M -98.26M -4.29B
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
17
Date Price Change Volume
26-06-12 5.800 $ +2.65% 174,785
26-06-11 5.650 $ +8.45% 508,937
26-06-10 5.210 $ +5.47% 149,934
26-06-09 4.940 $ -8.01% 297,732
26-06-08 5.370 $ -1.65% 303,350
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.650USD
Average target price
14.00USD
Spread / Average Target
+147.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!